PA8853201A1 - Formulaciones farmaceuticas de conjugados de camtotecina-polimero biocompatibles biodegradables - Google Patents

Formulaciones farmaceuticas de conjugados de camtotecina-polimero biocompatibles biodegradables

Info

Publication number
PA8853201A1
PA8853201A1 PA20098853201A PA8853201A PA8853201A1 PA 8853201 A1 PA8853201 A1 PA 8853201A1 PA 20098853201 A PA20098853201 A PA 20098853201A PA 8853201 A PA8853201 A PA 8853201A PA 8853201 A1 PA8853201 A1 PA 8853201A1
Authority
PA
Panama
Prior art keywords
camtotechina
pharmaceutical formulations
polymer conjugates
biodegradable biocompatible
polymer
Prior art date
Application number
PA20098853201A
Other languages
English (en)
Inventor
Rolke James
C Petter Russell
Yin Mao
Yurkovetskiy Aleksandr
Liu Giu
Farhan Emile
Original Assignee
Mersana Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42243068&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8853201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mersana Therapeutics Inc filed Critical Mersana Therapeutics Inc
Publication of PA8853201A1 publication Critical patent/PA8853201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE DESCRIBE UN SISTEMA DE LIBERACIÓN DE UN FÁRMACO DE FASE DUAL DE CAMPTOTECINA/POLÍMERO QUE ES ESTABLE TANTO EN ESTADO LÍQUIDO COMO LIOFILIZADO.EL POLÍMERO CONTIENE ACETALES Y/O CETALES.
PA20098853201A 2008-12-10 2009-12-10 Formulaciones farmaceuticas de conjugados de camtotecina-polimero biocompatibles biodegradables PA8853201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12138408P 2008-12-10 2008-12-10

Publications (1)

Publication Number Publication Date
PA8853201A1 true PA8853201A1 (es) 2010-07-27

Family

ID=42243068

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098853201A PA8853201A1 (es) 2008-12-10 2009-12-10 Formulaciones farmaceuticas de conjugados de camtotecina-polimero biocompatibles biodegradables

Country Status (9)

Country Link
US (2) US8491880B2 (es)
KR (1) KR20110102420A (es)
CN (1) CN102307473A (es)
AR (1) AR074584A1 (es)
CL (1) CL2009002167A1 (es)
PA (1) PA8853201A1 (es)
PE (1) PE20100746A1 (es)
TW (1) TW201036639A (es)
WO (1) WO2010068759A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2553019A1 (en) * 2010-03-26 2013-02-06 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
US20180157397A1 (en) * 2016-04-08 2018-06-07 Maxx Media Group, LLC System and Method for Adding Three-Dimensional Images to an Intelligent Virtual Assistant that Appear to Project Forward of or Vertically Above an Electronic Display
WO2017210566A1 (en) * 2016-06-03 2017-12-07 Novacyte, Inc. Polymer linkers and their uses
AU2017345454A1 (en) 2016-10-19 2019-05-30 Invenra Inc. Antibody constructs
MX2019007019A (es) 2016-12-22 2019-08-16 Univ Degli Studi Magna Graecia Catanzaro Anticuerpo monoclonal dirigido a un epitope de cd43 sialoglicosilado especifico asociado al cancer.
TW201905037A (zh) 2017-06-22 2019-02-01 美商梅爾莎納醫療公司 藥物攜帶聚合物支架及蛋白質聚合物藥物共軛物之製造方法
CN113227127A (zh) 2018-06-05 2021-08-06 伦敦大学国王学院 向胃肠系统递送酬载的btnl3/8导引构建体

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4793986A (en) 1987-02-25 1988-12-27 Johnson Matthey, Inc. Macromolecular platinum antitumor compounds
JPH01190636A (ja) 1988-01-22 1989-07-31 Green Cross Corp:The 制癌作用物質複合体
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
WO1994002068A1 (en) * 1992-07-21 1994-02-03 The General Hospital Corporation System of drug delivery to the lymphatic tissues
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5612037A (en) * 1994-07-26 1997-03-18 Connaught Laboratories, Inc. Influenza virus subunit conjugates
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
AU5122796A (en) * 1995-03-31 1996-10-16 Drug Delivery System Institute, Ltd. Amidite derivatives and oligonucleotide derivatives
US5811510A (en) * 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
AU6028396A (en) 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
AU735900B2 (en) 1996-03-12 2001-07-19 Pg-Txl Company, L.P. Water soluble paclitaxel prodrugs
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US6294170B1 (en) * 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6818630B1 (en) 1999-06-18 2004-11-16 Ml Laboratories Plc Biologically active materials
IL131074A0 (en) 1999-07-23 2001-03-19 Polygene Ltd A biodegradable polycation composition for delivery of an anionic macromolecule
WO2001010468A2 (en) 1999-08-09 2001-02-15 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
US6822086B1 (en) * 1999-08-09 2004-11-23 The General Hospital Corporation Drug-carrier complexes and methods of use thereof
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US7160924B2 (en) * 2002-07-19 2007-01-09 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
DE60131177T2 (de) * 2000-09-06 2008-08-07 AP Pharma, Inc., Redwood Abbaubare polyacetal-polymere
US7838619B2 (en) * 2002-01-14 2010-11-23 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
WO2003070823A2 (en) * 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
JP4800614B2 (ja) 2002-07-19 2011-10-26 ザ ジェネラル ホスピタル コーポレイション オキシム結合体、およびそれらの形成および使用のための方法
CN102516417B (zh) * 2002-09-06 2014-12-10 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
WO2004089311A2 (en) 2003-03-31 2004-10-21 Vectramed, Inc. Polymeric drug agents for the treatment of fibrotic disorders
DE602004032553D1 (de) * 2003-09-05 2011-06-16 Gen Hospital Corp Polyacetal-arzneimittelkonjugate als freisetzungssystem
EP1547580A1 (en) * 2003-12-23 2005-06-29 MediGene Oncology GmbH Loading of a camptothecin drug into colloidal nanoparticles
KR101121808B1 (ko) * 2007-01-31 2012-03-21 쥬오 덴끼 고교 가부시키가이샤 탄소 재료 및 그 제조 방법
NZ585547A (en) * 2007-11-28 2012-12-21 Mersana Therapeutics Inc Biocompatible biodegradable fumagillin analog conjugates
US20120171118A1 (en) 2009-06-12 2012-07-05 The General Hospital Corporation Treatment of meningeal and neural diseases

Also Published As

Publication number Publication date
PE20100746A1 (es) 2010-11-04
WO2010068759A1 (en) 2010-06-17
CL2009002167A1 (es) 2010-10-15
AR074584A1 (es) 2011-01-26
TW201036639A (en) 2010-10-16
KR20110102420A (ko) 2011-09-16
US20140004074A1 (en) 2014-01-02
CN102307473A (zh) 2012-01-04
US8491880B2 (en) 2013-07-23
US20100179181A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
PA8853201A1 (es) Formulaciones farmaceuticas de conjugados de camtotecina-polimero biocompatibles biodegradables
CY1119829T1 (el) Βιοαποικοδομησιμες συνθεσεις απελευθερωσης φαρμακου
BRPI1007325A2 (pt) "baixo peso molecular de polissulfatados derivados de ácido hialurônico e medicamentos que contenham o mesmo."
BRPI1014139A2 (pt) sistema de liberação de fármacos compreendendo polioxazolina e um agente biotivo.
BRPI0716196A2 (pt) Sistemas de distribuição de fármacos que compreendem soluções sólidas de fármacos fracamente básicos.
BRPI0820229A2 (pt) conjugados de análogos de fumagilina biodegradáveis biocompatíveis
WO2009140423A3 (en) Targeted polymer bioconjugates
BRPI0920690A2 (pt) sistema de distribuição de stent restringível
BRPI1012246A2 (pt) composição farmacêutica contendo um fármaco e sirna
BRPI0917030A2 (pt) sistema de liberação de fármaco contendo progestina
BR112013002431A2 (pt) sistema para a reconfirmação da posição de um cateter no interior de um paciente
BRPI0814759A2 (pt) Sistema de administração e notificação de medicamento específico de paciente
AR097045A2 (es) Sistema terapéutico transdérmico
WO2010027735A3 (en) Coating on a balloon comprising a polymer and a drug
BRPI0822026A2 (pt) Prepação farmacêutica ou nutracêutica revestida com liberação acentuada de substância ativa no cólon.
DE602007009388D1 (de) Implantierbare medizinprodukte aus verzweigten polymeren
BRPI1013754A2 (pt) módulo medicinal com proteção de agulha.
IT1394522B1 (it) Dispositivo medicale con rilascio di farmaco
BR112013001250A2 (pt) ''filme biodegradável; revestimento de liberação, artigo absorvente; e bolso, manta ou bolsa''
BR112012002981A2 (pt) sistema de liberação de fármaco oftálmico contendo fosfolipídio e colesterol.
BRPI0908208A2 (pt) Composto derivado de oxazolidinona, medicamento, composição farmacêutica que o contém e uso desse composto.
BRPI0908231A2 (pt) Sistema de liberação de fármaco com efeito estabilizante
WO2009147641A3 (en) A device and a system for delivery of biological material
WO2010099292A3 (en) Biodegradable drug or other active delivery system
BRPI0921365A2 (pt) cartucho, um dispensador de produtos farmacêuticos que contém o cartucho, bem como as aplicações do catucho e do dispensador de produtos farmacêuticos.